The stock of TESARO Inc (NASDAQ:TSRO) is a huge mover today! About 3.45M shares traded hands or 173.81% up from the average. TESARO Inc (NASDAQ:TSRO) has risen 232.59% since April 13, 2016 and is uptrending. It has outperformed by 228.66% the S&P500.
The move comes after 9 months negative chart setup for the $7.07B company. It was reported on Nov, 15 by Barchart.com. We have $121.03 PT which if reached, will make NASDAQ:TSRO worth $636.30M less.
TESARO Inc (NASDAQ:TSRO) Ratings Coverage
Out of 13 analysts covering Tesaro Inc (NASDAQ:TSRO), 11 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 85% are positive. Tesaro Inc has been the topic of 23 analyst reports since August 24, 2015 according to StockzIntelligence Inc. Wedbush maintained TESARO Inc (NASDAQ:TSRO) rating on Friday, August 5. Wedbush has “Outperform” rating and $107 price target. The rating was maintained by Mizuho on Friday, August 5 with “Buy”. Lake Street initiated it with “Buy” rating and $61 target price in Friday, February 5 report. The rating was initiated by Wells Fargo with “Outperform” on Friday, December 4. Wedbush initiated it with “Outperform” rating and $72 target price in Thursday, January 21 report. The firm has “Buy” rating by Citigroup given on Thursday, March 17. The firm has “Outperform” rating by Robert W. Baird given on Tuesday, July 19. Wedbush maintained it with “Outperform” rating and $139 target price in Monday, October 10 report. The stock of TESARO Inc (NASDAQ:TSRO) has “Sell” rating given on Tuesday, September 1 by Zacks. The rating was maintained by FBR Capital on Monday, October 10 with “Outperform”.
According to Zacks Investment Research, “Tesaro, Inc. is an oncology-focused biopharmaceutical company for cancer patients. The Company’s product portfolio consists of Rolapitant, a neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting, TSR-011, an orally available anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer and other cancer indications, and Niraparib, an orally active and potent poly (ADP-ribose) polymerase inhibitor for the treatment of patients with solid tumors. Tesaro, Inc. is based in Waltham, Massachusetts.”
Insitutional Activity: The institutional sentiment increased to 1.55 in 2016 Q2. Its up 0.32, from 1.23 in 2016Q1. The ratio improved, as 24 funds sold all TESARO Inc shares owned while 36 reduced positions. 34 funds bought stakes while 59 increased positions. They now own 44.90 million shares or 3.32% less from 46.44 million shares in 2016Q1.
Barclays Public Ltd Com, a United Kingdom-based fund reported 65,460 shares. Moreover, Smith Asset Management Grp Lp has 0.01% invested in TESARO Inc (NASDAQ:TSRO) for 4,830 shares. Geode Cap Ltd owns 237,044 shares or 0.01% of their US portfolio. Pacad Inv Ltd reported 2,800 shares or 0.03% of all its holdings. The Massachusetts-based Massachusetts Ma has invested 0.01% in TESARO Inc (NASDAQ:TSRO). The California-based California Employees Retirement has invested 0.01% in TESARO Inc (NASDAQ:TSRO). Passport Cap Lc last reported 1.13% of its portfolio in the stock. Moreover, Capital Impact Ltd Llc has 0.27% invested in TESARO Inc (NASDAQ:TSRO) for 6,820 shares. Raymond James Advsrs accumulated 5,640 shares or 0% of the stock. California State Teachers Retirement has 0.01% invested in the company for 51,584 shares. Two Sigma Secs Ltd Limited Liability Company holds 6,855 shares or 0.31% of its portfolio. Tocqueville Asset Lp has invested 0.03% of its portfolio in TESARO Inc (NASDAQ:TSRO). Highbridge Management holds 42,648 shares or 0.06% of its portfolio. Td Asset Management accumulated 113,153 shares or 0.02% of the stock. Millennium Management Ltd Liability Corp last reported 0.02% of its portfolio in the stock.
Insider Transactions: Since June 10, 2016, the stock had 0 insider buys, and 6 sales for $4.43 million net activity. On Friday, June 10 the insider English Edward C sold $285,274. Hanke Jeffrey H. sold 12,500 shares worth $929,321. Huber Martin H. Jr. had sold 408 shares worth $44,113.
More news for TESARO Inc (NASDAQ:TSRO) were recently published by: Marketwatch.com, which released: “Tesaro Inc. stock drops 11% after announcing public offering at $135 per share” on November 15, 2016. Rttnews.com‘s article titled: “Tesaro Inc. (TSRO) Is Losing Ground After Offering Announcement” and published on November 14, 2016 is yet another important article.
TSRO Company Profile
TESARO, Inc. (TESARO), incorporated on March 26, 2010, is an oncology-focused biopharmaceutical company. The Firm acquires, in-licenses and develops oncology product candidates. The Firm operates in business of developing and commercializing oncology-focused therapeutics segment. The Firm has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.